Organoids From Metastases of Prostate Cancer (OrMePro)

Centre Antoine Lacassagne

Status

Terminated

Conditions

Prostatic Neoplasm

Treatments

Other: extended biopsy

Study type

Interventional

Funder types

Other

Identifiers

NCT03952793

2018/63

Details and patient eligibility

About

The aim of the study is the development of the organoid culture technique from metastases from patients with advanced form of prostate cancer. Once the technique is set up, the organoid will serve to test several antitumor molecules.

Enrollment

1 patient

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with metastatic prostate cancer
Patient having a biopsy programmed as part of his care.
Patient having a biopsy programmed as part of hiscare.
Patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study.
INR <1.5; Platelets > 50000 / μL

Exclusion criteria

Patient under age of 18 years.
Patient under Plavix or Effient or Ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or Fondaparinux without possibility of suspension, or ReoPro without possibility of suspension for 24h and aPTT <50s and ACT <150s, or Integrilin or Aggrastat or Argatroban without possibility of suspension 4 H before the intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL> 50 mL / min or 3H to 5h if CrCL <50 mL / min before the intervention or and Pradaxa without possibility of suspension 2 to 3 days if CrCL> 50 mL / min or 3 to 5 days if CrCL <50 mL / min before the procedure
Patient under desmopressin acetate (DDAVP)
Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a detection of the HBs antigen or the presence of anti HBc antibodies without HBs antibody detectable.